Daxor Corporation

Daxor Corporation

DXR·NASDAQ

$11.09

+3.3%
HealthcareMedical - Instruments & Supplies

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

At a Glance

Live Snapshot
Market Cap$55.86M
EPS1.8400
P/E Ratio6.03
Earnings Date08/20/2026

dxr

Additional Paid-In Capital

Last Annual Value

15.53M

3-Year CAGR

6%

5-Year CAGR

6%

10-Year CAGR

4%

Daxor Corporation

Daxor Corporation Competitors Analysis of Additional Paid-In Capital

DXR · NASDAQ
CompanyAdditional Paid-In Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
15.53M
4.3%5.1%3.8% 
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
773.79M
12.0%10.4%N/A
143.17M
7.3%5.9%N/A
50.03M
17.2%17.2%N/A
0.00
N/AN/AN/A
573.27M
2.9%3.5%N/A
784.71M
6.7%8.9%24.6%
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
109.87M
21.1%-7.8%4.7%
3.31B
-0.1%0.0%0.2%
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
0.00
N/AN/AN/A
290.93M
6.4%7.4%N/A
Daxor Corporation

Daxor Corporation Fair Value Envelope

DXR · NASDAQ

Our analysis suggests that DXR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $11.0866, this represents a potential HIDDEN relative to our calculated worth for Daxor Corporation.

Intrinsic Value
Current Price: $11.0866